InMed Pharmaceuticals Inc.
INM
$2.76
$0.010.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 13.48% | -12.09% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.48% | -12.09% | |||
| Cost of Revenue | 66.87% | -15.61% | |||
| Gross Profit | -61.90% | -6.59% | |||
| SG&A Expenses | -14.46% | 9.26% | |||
| Depreciation & Amortization | -1.69% | -2.56% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.78% | 9.91% | |||
| Operating Income | 4.12% | -25.77% | |||
| Income Before Tax | 17.63% | -53.47% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 17.63% | -53.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.63% | -53.47% | |||
| EBIT | 4.12% | -25.77% | |||
| EBITDA | 4.18% | -26.68% | |||
| EPS Basic | 46.90% | -34.70% | |||
| Normalized Basic EPS | 46.90% | -34.69% | |||
| EPS Diluted | 46.90% | -34.70% | |||
| Normalized Diluted EPS | 46.90% | -34.69% | |||
| Average Basic Shares Outstanding | 55.13% | 13.93% | |||
| Average Diluted Shares Outstanding | 55.13% | 13.93% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||